US20230270138A1 - Method of manufacture and pasteurization of products containing undenatured collagen - Google Patents
Method of manufacture and pasteurization of products containing undenatured collagen Download PDFInfo
- Publication number
- US20230270138A1 US20230270138A1 US18/144,542 US202318144542A US2023270138A1 US 20230270138 A1 US20230270138 A1 US 20230270138A1 US 202318144542 A US202318144542 A US 202318144542A US 2023270138 A1 US2023270138 A1 US 2023270138A1
- Authority
- US
- United States
- Prior art keywords
- collagen
- treated
- temperature
- undenatured
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 110
- 108010035532 Collagen Proteins 0.000 title claims abstract description 110
- 229920001436 collagen Polymers 0.000 title claims abstract description 93
- 238000000034 method Methods 0.000 title claims abstract description 59
- 238000004519 manufacturing process Methods 0.000 title description 9
- 238000009928 pasteurization Methods 0.000 title description 8
- 230000000813 microbial effect Effects 0.000 claims abstract description 39
- 102000000503 Collagen Type II Human genes 0.000 claims description 32
- 108010041390 Collagen Type II Proteins 0.000 claims description 32
- 238000010438 heat treatment Methods 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 27
- 235000013305 food Nutrition 0.000 claims description 15
- 241000287828 Gallus gallus Species 0.000 claims description 13
- 235000013361 beverage Nutrition 0.000 claims description 11
- 238000011109 contamination Methods 0.000 claims description 10
- 210000001562 sternum Anatomy 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 7
- 241000271566 Aves Species 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 241000251468 Actinopterygii Species 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 5
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 244000299461 Theobroma cacao Species 0.000 claims description 2
- 235000015111 chews Nutrition 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 19
- 210000000845 cartilage Anatomy 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 150000003839 salts Chemical class 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 235000013330 chicken meat Nutrition 0.000 description 11
- 235000013336 milk Nutrition 0.000 description 9
- 239000008267 milk Substances 0.000 description 9
- 210000004080 milk Anatomy 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 238000000113 differential scanning calorimetry Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 4
- 230000002917 arthritic effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000010411 cooking Methods 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 210000003035 hyaline cartilage Anatomy 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000002076 thermal analysis method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 102000009736 Collagen Type XI Human genes 0.000 description 1
- 108010034789 Collagen Type XI Proteins 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000019990 fruit wine Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012569 microbial contaminant Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002184 nasal cartilage Anatomy 0.000 description 1
- 210000000492 nasalseptum Anatomy 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- -1 potassium chloride Chemical class 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/16—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by heating loose unpacked materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/04—Heat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to methods for the manufacture of undenatured collagen at elevated temperatures, which may be used in nutritional supplements and health care formulations.
- the invention relates to methods of reducing the microbial content of undenatured Type II collagen which is particularly useful in the treatment of arthritic and non-arthritic medical conditions in humans and other mammals, for example joint pain.
- Type II collagen be undenatured (e.g., its native, or natural, conformation) in order to be useful in treating arthritic and non-arthritic conditions.
- ELISA enzyme linked immunosorbent assay
- Schilling U.S. Pat. Nos. 7,083,820 and 7,846,487 which are directed to methods for producing undenatured Type II collagen which retains the collagen II in its original crosslinked, insoluble structure in a dehydrated, stabilized form.
- the Schilling patents disclose products of a process which comprises the dehydration and thus stabilization of the avian articular cartilage at less than traditional processing temperatures and in the presence of an ionizable salt that is not harmful to the consumer in the concentrations employed.
- chicken sternal cartilage is obtained from young chickens and treated with an antimicrobial agent such as a hypochlorite, a nitrate or nitrite before being ground to an average particle size of 0.25′′ (6 mm) and being dried in a fluid bed reactor to reduce the water content by about 50%.
- the dried comminuted chicken cartilage is then mixed with an ionizable salt, such as potassium chloride, and is dried with particular attention being paid to ensure that the temperature of the resulting product does not exceed 110° F. (43° C.) until the water content is below 2%. It is believed that the salt stabilizes the native collagen II protein in the articular cartilage against hydrolysis and degeneration of the crosslinked structure.
- the salt also acts as an antimicrobial stabilizer against the growth of pathogens and spoilage organisms both during the manufacturing process, which is oftentimes set at temperatures conducive for the growth of the aforementioned organisms, as well as during the extended storage of said product. While the presence of such salt is believed to reduce the microbial content of the composition over time, the curing process can be very time consuming requiring extended treatment to reduce the microbial load to within desired limits. Accordingly, there remains a desire to identify further methods by which the microbial content of collagen compositions can be reduced or substantially or completely eliminated in a relatively rapid manner without having a deleterious effect on the biological activity of the composition due to the denaturation of the collagen II active ingredient.
- Pasteurization is the method invented by Louis Pasteur in the 19th century by which spoilage of beverages such as milk, fruit juices, and wine could be reduced by the application of heat to reduce their microbial contents.
- Pasteurization is distinguished from sterilization, which is intended to kill all the micro-organisms. Sterilization is not commonly practiced with food and beverage products because of adverse effects on taste and quality of the food and beverage.
- pasteurization can affect qualities of the food but in more minor ways. For example, pasteurization is known to denature dairy proteins such as casein and whey but does not affect the nutritional quality of the treated milk. Different protocols for pasteurization are practiced for different products destined for different uses or having different intended storage times.
- Low-temperature, long-time (LTLT) pasteurization of milk heats the milk to 63° C. for at least 30 minutes and produces a product which is shelf stable upon delivery to the consumer for up to six days.
- High-temperature, short-time (HTST) pasteurization of milk heats milk to 72° C. for 15 seconds and provides a product which remains stable under refrigeration after delivery to the consumer for five to 15 days.
- Ultra-heat treating (UHT) treats the milk at a temperature of 140° C. for four seconds and essentially sterilizes the milk such that it may be stored for several months without refrigeration. Each of these processes denatures some of the milk proteins (casein and whey) to varying degrees with UHT treated milk being unsuitable for manufacture of cheese.
- microbial is intended to encompass bacterial, fungal (including yeasts) and viral contaminants that are undesired in a product for human or non-human mammal consumption.
- the present invention relates to the surprising finding that undenatured collagen compositions can be heated for extended time periods at elevated temperatures without significant denaturing of the collagen protein.
- the unexpected finding that matrix bound proteins, such as collagen embedded in chicken sternum, maintain their native conformational structure at high temperatures makes it possible to reduce the microbial content of various collagen containing biological products without denaturing the collagen protein.
- the invention provides methods of manufacturing undenatured collagen under heat treatment conditions capable of reducing the microbial load comprising subjecting said collagen composition to a temperature of at least 40° C. for a time of at least 2 seconds in a manner to reduce microbial contamination without denaturing the collagen protein by more than 10%.
- the extent of collagen protein denaturation is determined by the use of a specific antibody ELISA method that binds to the undenatured form of collagen. Such a method is in contrast to thermoanalytical techniques such as differential scanning calorimetry (DSC) that relies on physical transformation and phase transitions, which may not accurately determine the in situ biophysical state of the collagen proteins (e.g., native versus denatured) in the matrix.
- DSC differential scanning calorimetry
- prepared undenatured collagen protein not subjected to heat treatment is less denatured than collagen preparations subjected to heat treatment.
- no more than 5% or 3% or 1% of the original undenatured collagen preparation is expected to be denatured.
- the heat treating method may be carried out at various combinations of temperatures and times as disclosed herein and as would be appreciated by one of ordinary skill in the art when apprised by the data provided herein.
- the heating can be carried out at temperatures of at least 50° C., or at least 60° C., or at least 70° C., or at least 80° C., or at least 90° C., or at least 100° C., or at least 110° C., or at least 120° C., or at least 130° C., or at least 140° C., or at least 150° C., or at least 160° C., or at least 170° C., or at least 180° C., or at least 190° C., or at least 200° C.
- heating to reduce the microbial content of the composition may be carried out without reducing the content of undenatured collagen by greater than 10% at higher temperatures such as at least 90° C., or at least 100° C., or at least 110° C., or at least 120° C., or at least 130° C., or at least 140° C., or at least 150° C., or at least 160° C., or at least 170° C., or at least 180° C., or at least 190° C., or at least 200° C.
- the heating is carried out at 120° C. for 30 minutes or 60 minutes or for a time in between and is effective to substantially diminish the microbial load of the collagen composition while maintaining a substantial portion of the collagen in an undenatured state.
- the heat treatment may be carried out in a liquid, such a water and can also be carried out at pressures greater than atmospheric such as in an autoclave which can allow for higher heating temperatures.
- the heat treatments may be carried out in a dry oven having a relative humidity of less than 10%.
- the heating may also be carried out at elevated relative humidity levels of at least 20% or at least 30%, or greater.
- the heat treatment be carried out in the presence of an ionizable salt which can be any of a variety of such salts but which is preferably selected from the group of ingestible salts consisting of sodium chloride and potassium chloride.
- an ionizable salt which can be any of a variety of such salts but which is preferably selected from the group of ingestible salts consisting of sodium chloride and potassium chloride.
- collagen containing sternal material can be heated in boiling water for time periods of up to 5 minutes, or up to 10 minutes or up to 15 minutes to provide a starting material free of microbial contamination from which undenatured collagen can be isolated according to methods known in the art and described below.
- the collagen is produced by a method comprising a shearing step in which the collagen containing cartilage is comminuted to an average particle size of less than 15 mm and more preferably less than 10 mm and according to one embodiment has an average particle size of about 6 mm.
- Such collagen compositions can be produced using methods which include shearing, slicing, chopping and other mechanically disruptive steps.
- the methods of the invention may be carried out using any type of collagen including particularly fibrillar type collagens including Type I, Type II, Type III and Type V and Type XI collagen.
- the invention is directed to preparation and manufacture of Type II collagen compositions which are particularly useful for treatment of arthritis and non-arthritis conditions in humans and other mammals.
- Use of collagen derived from all mammalian and non-mammalian species is contemplated by the invention but preferred sources of undenatured Type II collagen are bovine, fish and porcine derived collagen with avian derived collagen and particularly chicken sternum derived collagen being typically used.
- Other sources of undenatured Type-II collagen may be used without departing from the present invention.
- the methods of the invention may also be used to simplify the production of beverages containing an undenatured collagen component.
- the undenatured collagen component need not be treated for microbial contamination before being combined with the other beverage components.
- the undenatured collagen component may be combined with the other beverage components and the entire combination subjected to a heating step so as to reduce microbial contamination and sealed as part of the “bottling” process. Such a heating step would pasteurize the entire product without denaturing substantial amounts of the collagen.
- the undenatured collagen component once heat treated, can be added to beverages, dairy products, and other food items or formulations (e.g., gummies, quick dissolve oral strips, chocolates, soft chews, etc.) previously heat treated, without compromising the overall safety of the beverage or the food item.
- other food items or formulations e.g., gummies, quick dissolve oral strips, chocolates, soft chews, etc.
- undenatured collagen products having a reduced microbial content produced according to heat treating methods described above and particularly those that comprise undenatured Type II collagen.
- FIG. 1 depicts the percentage of undenatured Type II collagen when treated at various temperatures for either 30 minutes or 60 minutes.
- FIG. 2 depicts the microbial load in a Type II collagen composition when treated at various temperatures for either 30 minutes or 60 minutes.
- the present invention relates to the surprising finding that undenatured collagen compositions can be heated for extended time periods at elevated temperatures in order to reduce their microbial content without denaturing the collagen protein.
- the sources of collagen are described above and include bovine, porcine, avian, and fish. Of particular importance is avian collagen, in particular chicken sternums. More specifically the invention provides methods of heat treating undenatured collagen to reduce microbial contamination comprising subjecting said collagen to a temperature of greater than 40° C. for a time period sufficient to reduce microbial contamination without denaturing more than 10% of the collagen protein.
- the matrix (sternum) from which the Type II collagen is derived may act as a “crystallizing” milieu that keeps the type II collagen from unfolding thereby making it highly resistant to heat denaturation. This is a surprising result sin
- a reduction in microbial content is contemplated to mean a 50% reduction in microbial content such as by counting colony forming units but is preferably contemplated to mean a 10-fold reduction in microbial content. It is recognized that good hygienic practices will usually produce collagen products having minimal microbial contamination. Nevertheless, because of the catastrophic consequences of even a very few or only one contaminated product reaching consumers, the present invention is intended to treat many uncontaminated products in order to ensure product safety.
- Undenatured collagen to which the methods of the invention may be applied includes that isolated by any of the various methods known to the art including
- undenatured collagen to which the methods of the invention may be applied includes that isolated by any of the various methods known to the art including those described in any of Moore U.S. Pat. Nos. 5,570,144, 5,529,786, 5,637,321 and 5,645,851 or of Schilling, U.S. Pat. Nos. 7,083,820 and 7,846,487, each hereby incorporated by reference in its entirety.
- undenatured collagen can be isolated according to a method comprising the steps of
- the process does not involve use of any proteolytic enzymes or cartilage matrix degrading enzymes so as to protect the native structure of Type II collagen.
- undenatured collagen containing cartilage is subject to heat treatment conditions capable of reducing the microbial load comprising.
- the heat treatment included heating of the collagen composition to a temperature of at least 40° C. for a time of at least 2 seconds in a manner to reduce microbial content without denaturing more than 20% of the collagen protein.
- the heat treatment may be carried out at temperatures of at least 40° C. or higher.
- the heat treatment may be at a temperature of at least 50° C., or at least 60° C., or at least 70° C., or at least 80° C., or at least 90° C., or at least 100° C., or at least 110° C., or at least 120° C., or at least 130° C., or at least 140° C., or at least 150° C., or at least 160° C., or at least 170° C., or at least 180° C., or at least 190° C., or at least 200° C. or greater.
- the heat treatment may take place for a short as a few seconds up to several minutes.
- the heat treatment may be for at least 2 seconds, typically at least 10 seconds or long, such as 30 seconds, or 1 minute.
- the heating may also be carried out for longer periods of time, such as 90 seconds, 2 minute 3 minutes or 5 minute or 10 minutes or 15 minutes. Longer periods of time may also be used, such as 20 minutes, 30 minutes or 60 minutes or longer.
- the period of time used can be determined based on the collagen source, or the process conditions used to manufacture the undenatured collagen. Generally, the temperature should not exceed 250° C. and the time should not exceed 120 minutes. The temperature and time used should be selected so as not to cause more than 20% of the collagen protein to become denatured. Ideally, not more than 10% of the collagen protein to become denatured, and typically not more than 5% of the collagen protein to become denatured using the process of the present invention.
- ionizable salt be blended with the product because it provides stability to the undenatured Type II collagen so that it can retain its native protein structure even when subjected to high temperatures and humidity for various time intervals.
- the ionizable salt is added to the undenatured Type II collagen containing cartilage in an amount of at least 1% by weight, prior to heat treating or drying. Typically, the ionizable salt is added in an amount of at least 5% by weight, and more typically at least 15% by weight of the undenatured Type II collagen containing cartilage.
- the ionizable salt should be consumable by mammals. Suitable salts include, for example, sodium or potassium chloride. Other salts that are consumable by mammals may also be used. Salt concentrations vary widely depending on the nature of the food material involved and the degree of stabilization desired.
- heat treatment is capable of reducing microbial content with minimal denaturation of the collagen protein where the collagen containing material was ground, chopped or otherwise physically comminuted such as to produce fragments having particle sizes of less than 15 mm and less than 10 mm in size because such physical treatment might render the collagen triple helix more susceptible to denaturation at lower temperatures and times due to the destruction (i.e., destabilization) of the complex proteoglycan matrix enveloping the collagen protein.
- undenatured Type II collagen was subjected to heating at specified temperatures and times to determine the ability to reduce the microbial content of the sample and whether such treatment denatured the collagen as measured by ELISA.
- undenatured Type II collagen was subjected to heating at specified temperatures and times to determine the ability to reduce the microbial content of the sample and whether such treatment denatured the collagen as measured by ELISA.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application is a continuation application of U.S. application Ser. No. 15/724,220, filed on Oct. 3, 2017, which claims benefit to U.S. Provisional Application No. 62/404,065, filed on Oct. 4, 2016, the disclosures of which are incorporated by reference herein in their entirety.
- The present invention relates to methods for the manufacture of undenatured collagen at elevated temperatures, which may be used in nutritional supplements and health care formulations.
- In particular, the invention relates to methods of reducing the microbial content of undenatured Type II collagen which is particularly useful in the treatment of arthritic and non-arthritic medical conditions in humans and other mammals, for example joint pain.
- Of interest to the present application are the disclosures of Moore U.S. Pat. Nos. 5,570,144, 5,529,786, 5,637,321 and 5,645,851 which are directed to the administration of chicken derived Type II collagen for the treatment of Rheumatoid Arthritis and Osteoarthritis. In addition, Dijkstra et al., U.S. Pat. No. 9,066,926 discloses a method of treating exercise and mechanically induced joint pain in arthritis-free mammals by the administration of Type II collagen (collagen II).
- It has further been observed that it is important that the Type II collagen be undenatured (e.g., its native, or natural, conformation) in order to be useful in treating arthritic and non-arthritic conditions. Such an undenatured conformation is best analyzed by means of enzyme linked immunosorbent assay (ELISA) methods, which utilize monoclonal or polyclonal antibodies to detect and to quantify the presence of the undenatured collagen molecule.
- Also of interest to the present invention are the disclosures of Schilling, U.S. Pat. Nos. 7,083,820 and 7,846,487 which are directed to methods for producing undenatured Type II collagen which retains the collagen II in its original crosslinked, insoluble structure in a dehydrated, stabilized form. The Schilling patents disclose products of a process which comprises the dehydration and thus stabilization of the avian articular cartilage at less than traditional processing temperatures and in the presence of an ionizable salt that is not harmful to the consumer in the concentrations employed. According to one aspect of the Schilling patents, chicken sternal cartilage is obtained from young chickens and treated with an antimicrobial agent such as a hypochlorite, a nitrate or nitrite before being ground to an average particle size of 0.25″ (6 mm) and being dried in a fluid bed reactor to reduce the water content by about 50%. The dried comminuted chicken cartilage is then mixed with an ionizable salt, such as potassium chloride, and is dried with particular attention being paid to ensure that the temperature of the resulting product does not exceed 110° F. (43° C.) until the water content is below 2%. It is believed that the salt stabilizes the native collagen II protein in the articular cartilage against hydrolysis and degeneration of the crosslinked structure. Nevertheless, the Schilling patents teach that fresh chicken sternal cartilage subjected to thermal processing at 250° F. (121° C.) for one hour contained less than 1% “almost unmeasurable” amounts of crosslinked (undenatured) collagen II after said treatment.
- During and after processing, the salt also acts as an antimicrobial stabilizer against the growth of pathogens and spoilage organisms both during the manufacturing process, which is oftentimes set at temperatures conducive for the growth of the aforementioned organisms, as well as during the extended storage of said product. While the presence of such salt is believed to reduce the microbial content of the composition over time, the curing process can be very time consuming requiring extended treatment to reduce the microbial load to within desired limits. Accordingly, there remains a desire to identify further methods by which the microbial content of collagen compositions can be reduced or substantially or completely eliminated in a relatively rapid manner without having a deleterious effect on the biological activity of the composition due to the denaturation of the collagen II active ingredient.
- Common methods for reducing the microbial content of food and other consumable ingredients is heat treatment (such as cooking), treatments with chemicals such as acids, alkalis and the like. Nevertheless, there is a desire to avoid “cooking” the source material because of the likelihood of denaturing the constituent collagen (s). Moreover, there is a desire to avoid chemical treatment of foods and other consumables. Even if the chemical treatment is as simple as acid or alkali treatment there is a similar desire to avoid such treatment because of concerns that such treatment will negatively affect the utility of the resulting composition such as by denaturing the protein structure of the collagen.
- Pasteurization is the method invented by Louis Pasteur in the 19th century by which spoilage of beverages such as milk, fruit juices, and wine could be reduced by the application of heat to reduce their microbial contents. Pasteurization is distinguished from sterilization, which is intended to kill all the micro-organisms. Sterilization is not commonly practiced with food and beverage products because of adverse effects on taste and quality of the food and beverage. Similarly, pasteurization can affect qualities of the food but in more minor ways. For example, pasteurization is known to denature dairy proteins such as casein and whey but does not affect the nutritional quality of the treated milk. Different protocols for pasteurization are practiced for different products destined for different uses or having different intended storage times. Low-temperature, long-time (LTLT) pasteurization of milk heats the milk to 63° C. for at least 30 minutes and produces a product which is shelf stable upon delivery to the consumer for up to six days. High-temperature, short-time (HTST) pasteurization of milk heats milk to 72° C. for 15 seconds and provides a product which remains stable under refrigeration after delivery to the consumer for five to 15 days. Ultra-heat treating (UHT) treats the milk at a temperature of 140° C. for four seconds and essentially sterilizes the milk such that it may be stored for several months without refrigeration. Each of these processes denatures some of the milk proteins (casein and whey) to varying degrees with UHT treated milk being unsuitable for manufacture of cheese.
- Not only does there exist an ongoing concern regarding the possibility of infection resulting from uncooked or undercooked food products but a similar concern also exists from the use of animal sources for food and nutraceutical ingredients where those animal sources are not cooked or subjected to sterilization procedures prior to extraction of ingredients ultimately intended for human and other mammalian consumption.
- Accordingly, there remains a desire in the art to identify methods for reducing the microbial content of collagen compositions extracted from uncooked, unsterilized animal sources such as chickens, cows, pigs, fish and other animals. As used herein “microbial” is intended to encompass bacterial, fungal (including yeasts) and viral contaminants that are undesired in a product for human or non-human mammal consumption.
- Of interest to the present invention is the finding of Cao et al., Food Chemistry 108: 439-445 (2008) which discloses the purification of Type II collagen from chick sternal cartilage using a combination of pepsin digestion, NaCl precipitation and DEAE-sepharose ion exchange chromatography. Both purified and matrix bound collagen (i.e., intact sternal cartilage) were heated according to a protocol whereby the sample temperature was increased by 5° C. each minute and the denaturation temperature was determined to be 44° C. for both materials, using differential scanning calorimetry (DSC) which measures phase changes in the heated samples. Such results indicate that the presence of collagen in a sternal or other biological matrix does not impact the temperature at which this protein denatures.
- Also of interest to the present invention is the disclosure of Than et al., J. Thermal Analysis and calorimetry Vol. 82, 213-216 (2005) which described a thermal analysis of osteoarthritic human hyaline cartilage which reported an endothermic reaction at around 60° C.
- Ignat'eva et al., Russian, J. Phys. Chem Vol 80, No. 8 1336-1341 (2006) reported on the thermal stability of collagen II in various cartilaginous tissues including nucleus pulposus (vertebral disc) showing melting within a temperature range of 60-70° C. and hyaline cartilage of nasal septum and cartilage endplates which was said to be not denatured completely up to 100° C.
- Also of interest to the present invention is the disclosure of Logunova et al., Biophysics Vol 53, No. 5:470-475 which provides other DSC data regarding collagen thermal stability. While perichondrium derived cartilage was reported to have a melting (denaturation) temperature of 65° C., the hyaline constituent of collagen was indicated to not denature at temperatures up to 100° C. Of significance to the present invention is the fact that while DSC analysis measures endothermic and exothermic transitions in the analyzed materials, which can be indicative of phase changes, it does not necessarily measure the biological activity or conformational structures of each component of a complex sample matrix containing multiple biological materials, including proteins. As such, DSC may not measure subtle variations in protein structure that can result in changes in biological activity. This limitation would not apply to mixtures containing a single component protein, but may when the complex sample contains multiple proteins, proteoglycans and other constituents as is generally the case with tissues such as the sternal cartilage.
- There remains a desire in the art to develop methods for reducing the microbial content of collagen compositions without denaturing the collagen and thereby preserve the biological activity of the collagen.
- The present invention relates to the surprising finding that undenatured collagen compositions can be heated for extended time periods at elevated temperatures without significant denaturing of the collagen protein. The unexpected finding that matrix bound proteins, such as collagen embedded in chicken sternum, maintain their native conformational structure at high temperatures makes it possible to reduce the microbial content of various collagen containing biological products without denaturing the collagen protein. More specifically, the invention provides methods of manufacturing undenatured collagen under heat treatment conditions capable of reducing the microbial load comprising subjecting said collagen composition to a temperature of at least 40° C. for a time of at least 2 seconds in a manner to reduce microbial contamination without denaturing the collagen protein by more than 10%. As provided herein the extent of collagen protein denaturation is determined by the use of a specific antibody ELISA method that binds to the undenatured form of collagen. Such a method is in contrast to thermoanalytical techniques such as differential scanning calorimetry (DSC) that relies on physical transformation and phase transitions, which may not accurately determine the in situ biophysical state of the collagen proteins (e.g., native versus denatured) in the matrix.
- According to preferred methods, prepared undenatured collagen protein not subjected to heat treatment, is less denatured than collagen preparations subjected to heat treatment. However, following the application of said heat treatment no more than 5% or 3% or 1% of the original undenatured collagen preparation is expected to be denatured.
- It is further contemplated that the heat treating method may be carried out at various combinations of temperatures and times as disclosed herein and as would be appreciated by one of ordinary skill in the art when apprised by the data provided herein. Thus, the heating can be carried out at temperatures of at least 50° C., or at least 60° C., or at least 70° C., or at least 80° C., or at least 90° C., or at least 100° C., or at least 110° C., or at least 120° C., or at least 130° C., or at least 140° C., or at least 150° C., or at least 160° C., or at least 170° C., or at least 180° C., or at least 190° C., or at least 200° C. or greater, for at least 2 seconds and more preferably 30 seconds, or 1 minute. The heating may also be carried out for 3 minutes or 5 minute or 10 minutes or 15 minutes but may also be carried out for other time periods such as 20 minutes, 30 minutes or 60 minutes or longer. As a further aspect of the invention it is contemplated that heating to reduce the microbial content of the composition may be carried out without reducing the content of undenatured collagen by greater than 10% at higher temperatures such as at least 90° C., or at least 100° C., or at least 110° C., or at least 120° C., or at least 130° C., or at least 140° C., or at least 150° C., or at least 160° C., or at least 170° C., or at least 180° C., or at least 190° C., or at least 200° C. or greater, for time periods of at least 2 seconds to 10 minutes, or 10 minutes to 20 minutes or longer up to one hour. According to a particularly preferred aspect of the invention the heating is carried out at 120° C. for 30 minutes or 60 minutes or for a time in between and is effective to substantially diminish the microbial load of the collagen composition while maintaining a substantial portion of the collagen in an undenatured state. It is further contemplated that the heat treatment may be carried out in a liquid, such a water and can also be carried out at pressures greater than atmospheric such as in an autoclave which can allow for higher heating temperatures.
- The heat treatments may be carried out in a dry oven having a relative humidity of less than 10%. Alternatively, the heating may also be carried out at elevated relative humidity levels of at least 20% or at least 30%, or greater.
- In an additional embodiment of the invention, it is further contemplated that the heat treatment be carried out in the presence of an ionizable salt which can be any of a variety of such salts but which is preferably selected from the group of ingestible salts consisting of sodium chloride and potassium chloride.
- According to one aspect of the invention collagen containing sternal material can be heated in boiling water for time periods of up to 5 minutes, or up to 10 minutes or up to 15 minutes to provide a starting material free of microbial contamination from which undenatured collagen can be isolated according to methods known in the art and described below.
- According to one aspect of the invention, the collagen is produced by a method comprising a shearing step in which the collagen containing cartilage is comminuted to an average particle size of less than 15 mm and more preferably less than 10 mm and according to one embodiment has an average particle size of about 6 mm. Such collagen compositions can be produced using methods which include shearing, slicing, chopping and other mechanically disruptive steps.
- The methods of the invention may be carried out using any type of collagen including particularly fibrillar type collagens including Type I, Type II, Type III and Type V and Type XI collagen. In particularly the invention is directed to preparation and manufacture of Type II collagen compositions which are particularly useful for treatment of arthritis and non-arthritis conditions in humans and other mammals. Use of collagen derived from all mammalian and non-mammalian species is contemplated by the invention but preferred sources of undenatured Type II collagen are bovine, fish and porcine derived collagen with avian derived collagen and particularly chicken sternum derived collagen being typically used. Other sources of undenatured Type-II collagen may be used without departing from the present invention.
- While collagen compositions have customarily been delivered in a dry format, such as in tablets or capsules, the methods of the invention may also be used to simplify the production of beverages containing an undenatured collagen component. According to this aspect of the invention, the undenatured collagen component need not be treated for microbial contamination before being combined with the other beverage components. Instead, the undenatured collagen component may be combined with the other beverage components and the entire combination subjected to a heating step so as to reduce microbial contamination and sealed as part of the “bottling” process. Such a heating step would pasteurize the entire product without denaturing substantial amounts of the collagen. Alternatively, the undenatured collagen component, once heat treated, can be added to beverages, dairy products, and other food items or formulations (e.g., gummies, quick dissolve oral strips, chocolates, soft chews, etc.) previously heat treated, without compromising the overall safety of the beverage or the food item.
- Also provided by the invention are undenatured collagen products having a reduced microbial content produced according to heat treating methods described above and particularly those that comprise undenatured Type II collagen.
-
FIG. 1 depicts the percentage of undenatured Type II collagen when treated at various temperatures for either 30 minutes or 60 minutes; and -
FIG. 2 depicts the microbial load in a Type II collagen composition when treated at various temperatures for either 30 minutes or 60 minutes. - The present invention relates to the surprising finding that undenatured collagen compositions can be heated for extended time periods at elevated temperatures in order to reduce their microbial content without denaturing the collagen protein. The sources of collagen are described above and include bovine, porcine, avian, and fish. Of particular importance is avian collagen, in particular chicken sternums. More specifically the invention provides methods of heat treating undenatured collagen to reduce microbial contamination comprising subjecting said collagen to a temperature of greater than 40° C. for a time period sufficient to reduce microbial contamination without denaturing more than 10% of the collagen protein. Without intending to be bound by any particular theory of the invention it is hypothesized that the matrix (sternum) from which the Type II collagen is derived may act as a “crystallizing” milieu that keeps the type II collagen from unfolding thereby making it highly resistant to heat denaturation. This is a surprising result sin
- As used herein, a reduction in microbial content is contemplated to mean a 50% reduction in microbial content such as by counting colony forming units but is preferably contemplated to mean a 10-fold reduction in microbial content. It is recognized that good hygienic practices will usually produce collagen products having minimal microbial contamination. Nevertheless, because of the catastrophic consequences of even a very few or only one contaminated product reaching consumers, the present invention is intended to treat many uncontaminated products in order to ensure product safety.
- Undenatured collagen to which the methods of the invention may be applied includes that isolated by any of the various methods known to the art including
-
- 1. Receiving of raw chicken sternums;
- 2. Optionally washing the sternums with antimicrobial agent(s), as required;
- 3. Drying of the sternal cartilage at temperatures below 40° C.;
- 4. Grinding the dry cartilage;
- 5. Milling the blend to a desired particle size.
Alternatively, the drying of the sternal cartilage could take place above 40° C., in accordance with the present invention.
- Alternatively, undenatured collagen to which the methods of the invention may be applied includes that isolated by any of the various methods known to the art including those described in any of Moore U.S. Pat. Nos. 5,570,144, 5,529,786, 5,637,321 and 5,645,851 or of Schilling, U.S. Pat. Nos. 7,083,820 and 7,846,487, each hereby incorporated by reference in its entirety. Those of ordinary skill in the art would appreciate that such undenatured collagen can be isolated according to a method comprising the steps of
-
- 1. Receiving of raw chicken sternums;
- 2. Washing the sternums with antimicrobial agent(s) as required;
- 3. Drying of the sternal cartilage at temperatures below 40° C.;
- 4. Grinding the dry cartilage;
- 5. Adding ionizable salt (KCl or NaCl or others) to the ground cartilage;
- 6. Re-grinding and blending of salt with the ground cartilage;
- 7. Drying the blend;
- 8. Milling the blend to a desired particle size.
- According to one aspect of the invention it is desired that the process does not involve use of any proteolytic enzymes or cartilage matrix degrading enzymes so as to protect the native structure of Type II collagen.
- In the process of the present invention, undenatured collagen containing cartilage is subject to heat treatment conditions capable of reducing the microbial load comprising. The heat treatment included heating of the collagen composition to a temperature of at least 40° C. for a time of at least 2 seconds in a manner to reduce microbial content without denaturing more than 20% of the collagen protein. The heat treatment may be carried out at temperatures of at least 40° C. or higher. For example the heat treatment may be at a temperature of at least 50° C., or at least 60° C., or at least 70° C., or at least 80° C., or at least 90° C., or at least 100° C., or at least 110° C., or at least 120° C., or at least 130° C., or at least 140° C., or at least 150° C., or at least 160° C., or at least 170° C., or at least 180° C., or at least 190° C., or at least 200° C. or greater. The heat treatment may take place for a short as a few seconds up to several minutes. For example, the heat treatment may be for at least 2 seconds, typically at least 10 seconds or long, such as 30 seconds, or 1 minute. The heating may also be carried out for longer periods of time, such as 90 seconds, 2 minute 3 minutes or 5 minute or 10 minutes or 15 minutes. Longer periods of time may also be used, such as 20 minutes, 30 minutes or 60 minutes or longer. The period of time used can be determined based on the collagen source, or the process conditions used to manufacture the undenatured collagen. Generally, the temperature should not exceed 250° C. and the time should not exceed 120 minutes. The temperature and time used should be selected so as not to cause more than 20% of the collagen protein to become denatured. Ideally, not more than 10% of the collagen protein to become denatured, and typically not more than 5% of the collagen protein to become denatured using the process of the present invention.
- It is further preferred that ionizable salt be blended with the product because it provides stability to the undenatured Type II collagen so that it can retain its native protein structure even when subjected to high temperatures and humidity for various time intervals. The ionizable salt is added to the undenatured Type II collagen containing cartilage in an amount of at least 1% by weight, prior to heat treating or drying. Typically, the ionizable salt is added in an amount of at least 5% by weight, and more typically at least 15% by weight of the undenatured Type II collagen containing cartilage. The ionizable salt should be consumable by mammals. Suitable salts include, for example, sodium or potassium chloride. Other salts that are consumable by mammals may also be used. Salt concentrations vary widely depending on the nature of the food material involved and the degree of stabilization desired.
- According to one aspect of the invention it is particularly surprising that heat treatment is capable of reducing microbial content with minimal denaturation of the collagen protein where the collagen containing material was ground, chopped or otherwise physically comminuted such as to produce fragments having particle sizes of less than 15 mm and less than 10 mm in size because such physical treatment might render the collagen triple helix more susceptible to denaturation at lower temperatures and times due to the destruction (i.e., destabilization) of the complex proteoglycan matrix enveloping the collagen protein.
- According to this example undenatured Type II collagen was subjected to heating at specified temperatures and times to determine the ability to reduce the microbial content of the sample and whether such treatment denatured the collagen as measured by ELISA.
- The results presented in Table 1 below show that heating sample of undenatured Type-II collagen (<10% moisture content) in an oven for 15 minutes acted to reduce the total mold count at various temperatures but did not destroy (e.g., denature) the tertiary structure of the undenatured Type II collagen at temperatures as high as 90° C. (dry heat). Because the samples treated were generally free of other microbial contaminants additional testing is contemplated which will demonstrate the efficacy of such heat treatment in reducing other microbial contamination while also failing to denature the Type II collagen under other time, temperature and moisture conditions.
-
Sample 1 2 3 4 5 6 7 Incubation temp. (° C., dry heat in oven) Pre-incubation 40 50 60 70 80 90 Incubation time (min) — 15 Results Undenatured type II collagen (by IH validated ELISA) 10.6% 10.2% 9.16% 10.6% 11.4% 11.8% 9.56% Total Aerobic microbial count (CFU/g) (by USP 2021) <10 <10 <10 <10 <10 <10 <10 Total mold count (CFU/g) (by USP 2021) 20 <10 <10 <10 <10 <10 <10 Total yeast count (CFU/g) (by USP 2021) <10 <10 <10 <10 <10 <10 <10 Escherichia coli (by USP 2022) Neg. Neg. Neg. Neg. Neg. Neg. Neg. Salmonella (by USP 2022) Neg. Neg. Neg. Neg. Neg. Neg. Neg. Staphylococcus aureus (by USP 2022) Neg. Neg. Neg. Neg. Neg. Neg. Neg. - According to this example undenatured Type II collagen was subjected to heating at specified temperatures and times to determine the ability to reduce the microbial content of the sample and whether such treatment denatured the collagen as measured by ELISA.
- The results shown in
FIGS. 1 and 2 show the percentage of undenatured Type II collagen when treated at various temperatures for either 30 minutes or 60 minutes (FIG. 1 ) as well as the microbial load after such high temperature treatment (FIG. 2 ) compared with a control. These results show that undenatured Type II collagen is stable from 40° C. to 200° C. when heated for 30 minutes or less (seeFIG. 1 ). At temperatures of 120° C. and higher, the endogenous aerobic count of UC-II are reduced to 10-100 cfu per gram (starting plate count=1400 cfu/gm). At temperatures beyond 120° C., 60 minute treatments start to significantly reduce the percentage of Type II collagen which remains undenatured. By 200° C., very little undenatured Type II collagen remains when treated for 60 minutes. - The results also showed that treatment for 30 minutes to 60 minutes at 120° C. will diminish the endogenous (aerobic) microbial load of the Type II collagen. At temperatures of 120° C. and above, all Bacillus cereus and Salmonella strains (typhimurium and heidelberg) are killed to the 5 logs. Other experiments established that S. typhimurium can be killed to 6 logs after treatment at 110° C. for 30 minutes.
- These results suggest that treatment at 120° C. for 30 minutes to 60 minutes may be preferred for commercial production.
- Shown below in Table 2 below are analyses of Type II collagen products subjected to heating at 120° C. for 30 minutes and 60 minutes and compared to untreated such as for purposes of regulatory approval requiring a demonstration that high temperature baking or cooking of an ingredient causes only minor loss of volatile components and no other changes to the chemical or molecular composition or structure of the ingredient.
-
TABLE 2 120° C., 120° C., Chemical Parameter Untreated 30 min 60 min Carbohydrate, total (%) 12.2 12.9 12.3 Fat (%) 0.94 0.84 0.87 Loss on Drying (%) 5.18 4.85 4.46 Protein (%) 44.5 44.3 45.0 Protein Factor 6.25 6.25 6.25 Ash (%) 37.2 37.1 37.4 Chondroitin Sulfate (mg/g) 89.6 90.6 82.3 Collagen (mg/g) 294 266 296 Total Collagen (mg/g) 36.7 33.3 37.0 Undenatured Collagen (%)* 10.0 10.6 14.1 - Numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the presently preferred embodiments thereof. Consequently, the only limitations which should be placed upon the scope of the invention are those which appear in the appended claims.
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/144,542 US20230270138A1 (en) | 2016-10-04 | 2023-05-08 | Method of manufacture and pasteurization of products containing undenatured collagen |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662404065P | 2016-10-04 | 2016-10-04 | |
US15/724,220 US11793217B1 (en) | 2016-10-04 | 2017-10-03 | Method of manufacture and pasteurization of products containing undenatured collagen |
US18/144,542 US20230270138A1 (en) | 2016-10-04 | 2023-05-08 | Method of manufacture and pasteurization of products containing undenatured collagen |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/724,220 Continuation US11793217B1 (en) | 2016-10-04 | 2017-10-03 | Method of manufacture and pasteurization of products containing undenatured collagen |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230270138A1 true US20230270138A1 (en) | 2023-08-31 |
Family
ID=87762339
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/724,220 Active 2038-07-16 US11793217B1 (en) | 2016-10-04 | 2017-10-03 | Method of manufacture and pasteurization of products containing undenatured collagen |
US18/144,542 Pending US20230270138A1 (en) | 2016-10-04 | 2023-05-08 | Method of manufacture and pasteurization of products containing undenatured collagen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/724,220 Active 2038-07-16 US11793217B1 (en) | 2016-10-04 | 2017-10-03 | Method of manufacture and pasteurization of products containing undenatured collagen |
Country Status (1)
Country | Link |
---|---|
US (2) | US11793217B1 (en) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3695890A (en) * | 1970-11-02 | 1972-10-03 | Devro Inc | Collagen pulp beverage texturizer |
WO1993008784A1 (en) | 1991-11-08 | 1993-05-13 | Gunilla Lofgren Nisser | Partially occluded contact lens for treating visual and/or brain disorder |
US5645851A (en) | 1994-02-28 | 1997-07-08 | Moore; Eugene R. | Product for alleviating the symptons of arthritis in mammals |
US5529786A (en) | 1994-02-28 | 1996-06-25 | Moore; Eugene R. | Process and product for treatment of rheumatoid arthritis |
US5637321A (en) | 1994-02-28 | 1997-06-10 | Moore; Eugene R. | Method for preparing animal tissue for use in alleviating the symptoms of arthritis in mammals |
US7083820B2 (en) | 2000-09-29 | 2006-08-01 | Schilling Marvin L | Method for producing biologically active products |
WO2008133284A1 (en) * | 2007-04-25 | 2008-11-06 | Arkray, Inc. | Flavor-improving agent for foods and drinks |
JP5451975B2 (en) * | 2008-02-13 | 2014-03-26 | 株式会社ロッテ | Method for deodorizing collagen peptides |
WO2011037534A1 (en) * | 2009-09-25 | 2011-03-31 | Agency For Science, Technology And Research | A wafer level package and a method of forming a wafer level package |
US9343441B2 (en) * | 2012-02-13 | 2016-05-17 | Cree, Inc. | Light emitter devices having improved light output and related methods |
US9655951B2 (en) * | 2013-01-23 | 2017-05-23 | Cartilast II LLC | Preservation of the biological activity of undenatured type II collagen |
CA2846644C (en) | 2013-10-24 | 2018-05-01 | Paul Dijkstra | Method of reducing exercise-induced joint pain in non-arthritic mammals |
CN104161287A (en) * | 2014-08-29 | 2014-11-26 | 广西博士海意信息科技有限公司 | Collagen citrus beverage and making method thereof |
-
2017
- 2017-10-03 US US15/724,220 patent/US11793217B1/en active Active
-
2023
- 2023-05-08 US US18/144,542 patent/US20230270138A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11793217B1 (en) | 2023-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Alegbeleye et al. | Hazards of a ‘healthy’trend? An appraisal of the risks of raw milk consumption and the potential of novel treatment technologies to serve as alternatives to pasteurization | |
Nout et al. | Assessment of fermentation as a household technology for improving food safety: a joint FAO/WHO workshop | |
Nájera et al. | A review of the preservation of hard and semi-hard cheeses: Quality and safety | |
Al-Baarri et al. | Extending shelf life of indonesian soft milk cheese (dangke) by lactoperoxidase system and lysozyme | |
Hussein et al. | Shiga toxin–producing Escherichia coli: pre-and postharvest control measures to ensure safety of dairy cattle products | |
Berry et al. | Effects of freezing on nutritional and microbiological properties of foods | |
Gutema et al. | Microbial quality of traditionally dried fish products from selected parts of Ethiopia | |
Vranješ et al. | Raw milk consumption and health | |
US20230270138A1 (en) | Method of manufacture and pasteurization of products containing undenatured collagen | |
Tribst et al. | Heat treatment design for the valorization of sheep cheese whey in artisanal production | |
CN106578836A (en) | Application of polypeptides in food preservation | |
Leśnierowski | 26. Lysozyme and its modified forms: properties, potential for its production and application | |
CN105076351A (en) | Preservation method of egg liquid | |
Mahgoub | Fermented food in Egypt: a sustainable bio-preservation to improve the safety of food | |
KR20010103204A (en) | Methods for manufacturing low-salt fermented sea foods in short time and for improving their storage stability | |
Banerjee et al. | Recent trends in milk processing-A short review | |
US20040091470A1 (en) | Use of bacterial phage associated lytic enzymes to prevent food poisoning | |
Rimsha et al. | Safety and Quality Assessment of Milk Before and After Pasteurization Collected from Different Regions of Punjab | |
JPH02177852A (en) | Sterilization of ground fish meat | |
Kamau et al. | Effect of lactoperoxidase-thiocyanate-hydrogen peroxide system and storage temperature on keeping quality of raw camel milk | |
Le | Intense pulsed light decontamination of dairy powders: Effects on Bacillus cereus and Bacillus licheniformis spores, and dairy powder functionality | |
Taylor et al. | Lysozyme | |
Baron et al. | Microbial spoilage | |
Kasbullah et al. | Physical quality of pasteurized milk with the addition of straw ash water at different storage times | |
Motarjemi et al. | Practical applications: prospects and pitfalls |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LONZA CONSUMER HEALTH INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:INTERHEALTH NUTRACEUTICALS INCORPORATED;REEL/FRAME:063602/0745 Effective date: 20200227 Owner name: INTERHEALTH NUTRACEUTICALS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LUGO, JAMES PATRICK;SAIYED, ZAINULABEDIN MOHAMEDALI;REEL/FRAME:063600/0465 Effective date: 20170105 Owner name: LONZA GREENWOOD LLC, SOUTH CAROLINA Free format text: CHANGE OF NAME;ASSIGNOR:CAPSUGEL MANUFACTURING, LLC;REEL/FRAME:063621/0513 Effective date: 20220301 Owner name: CAPSUGEL MANUFACTURING, LLC, SOUTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LONZA CONSUMER HEALTH INC.;REEL/FRAME:063600/0879 Effective date: 20220301 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |